Browse TAZ

Summary
SymbolTAZ
Nametafazzin
Aliases BTHS; G4.5; Barth syndrome; CMD3A; EFE2; EFE; endocardial fibroelastosis 2; cardiomyopathy, dilated 3A (X-li ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Membrane; Single-pass membrane protein.; SUBCELLULAR LOCATION: Isoform 2: Cytoplasm ; SUBCELLULAR LOCATION: Isoform 3: Membrane; Single-pass membrane protein.; SUBCELLULAR LOCATION: Isoform 4: Membrane; Single-pass membrane protein.; SUBCELLULAR LOCATION: Isoform 5: Membrane; Single-pass membrane protein.; SUBCELLULAR LOCATION: Isoform 6: Cytoplasm ; SUBCELLULAR LOCATION: Isoform 7: Membrane; Single-pass membrane protein.; SUBCELLULAR LOCATION: Isoform 8: Cytoplasm ; SUBCELLULAR LOCATION: Isoform 9: Cytoplasm
Domain PF01553 Acyltransferase
Function

Some isoforms may be involved in cardiolipin (CL) metabolism.

> Gene Ontology
 
Biological Process GO:0003012 muscle system process
GO:0003013 circulatory system process
GO:0003015 heart process
GO:0006091 generation of precursor metabolites and energy
GO:0006119 oxidative phosphorylation
GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0006655 phosphatidylglycerol biosynthetic process
GO:0006936 muscle contraction
GO:0006941 striated muscle contraction
GO:0007006 mitochondrial membrane organization
GO:0007007 inner mitochondrial membrane organization
GO:0007507 heart development
GO:0007517 muscle organ development
GO:0007519 skeletal muscle tissue development
GO:0008015 blood circulation
GO:0008654 phospholipid biosynthetic process
GO:0009116 nucleoside metabolic process
GO:0009119 ribonucleoside metabolic process
GO:0009123 nucleoside monophosphate metabolic process
GO:0009126 purine nucleoside monophosphate metabolic process
GO:0009141 nucleoside triphosphate metabolic process
GO:0009144 purine nucleoside triphosphate metabolic process
GO:0009150 purine ribonucleotide metabolic process
GO:0009161 ribonucleoside monophosphate metabolic process
GO:0009167 purine ribonucleoside monophosphate metabolic process
GO:0009199 ribonucleoside triphosphate metabolic process
GO:0009205 purine ribonucleoside triphosphate metabolic process
GO:0010257 NADH dehydrogenase complex assembly
GO:0014706 striated muscle tissue development
GO:0015980 energy derivation by oxidation of organic compounds
GO:0022900 electron transport chain
GO:0022904 respiratory electron transport chain
GO:0032048 cardiolipin metabolic process
GO:0032049 cardiolipin biosynthetic process
GO:0032981 mitochondrial respiratory chain complex I assembly
GO:0033108 mitochondrial respiratory chain complex assembly
GO:0035965 cardiolipin acyl-chain remodeling
GO:0042278 purine nucleoside metabolic process
GO:0042407 cristae formation
GO:0042773 ATP synthesis coupled electron transport
GO:0042775 mitochondrial ATP synthesis coupled electron transport
GO:0045017 glycerolipid biosynthetic process
GO:0045333 cellular respiration
GO:0046034 ATP metabolic process
GO:0046128 purine ribonucleoside metabolic process
GO:0046471 phosphatidylglycerol metabolic process
GO:0046474 glycerophospholipid biosynthetic process
GO:0046486 glycerolipid metabolic process
GO:0048738 cardiac muscle tissue development
GO:0060047 heart contraction
GO:0060048 cardiac muscle contraction
GO:0060537 muscle tissue development
GO:0060538 skeletal muscle organ development
GO:0097031 mitochondrial respiratory chain complex I biogenesis
GO:1901657 glycosyl compound metabolic process
Molecular Function GO:0003841 1-acylglycerol-3-phosphate O-acyltransferase activity
GO:0008374 O-acyltransferase activity
GO:0016411 acylglycerol O-acyltransferase activity
GO:0016746 transferase activity, transferring acyl groups
GO:0016747 transferase activity, transferring acyl groups other than amino-acyl groups
GO:0042171 lysophosphatidic acid acyltransferase activity
GO:0047184 1-acylglycerophosphocholine O-acyltransferase activity
GO:0071617 lysophospholipid acyltransferase activity
Cellular Component GO:0005743 mitochondrial inner membrane
> KEGG and Reactome Pathway
 
KEGG hsa00564 Glycerophospholipid metabolism
Reactome R-HSA-1482798: Acyl chain remodeling of CL
R-HSA-1483206: Glycerophospholipid biosynthesis
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-392499: Metabolism of proteins
R-HSA-1268020: Mitochondrial protein import
R-HSA-1483257: Phospholipid metabolism
Summary
SymbolTAZ
Nametafazzin
Aliases BTHS; G4.5; Barth syndrome; CMD3A; EFE2; EFE; endocardial fibroelastosis 2; cardiomyopathy, dilated 3A (X-li ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TAZ and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TAZ and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29339539Breast carcinoma; Lung carcinomaInhibit immunityThe Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1. The Hippo pathway component WW domain-containing transcription regulator 1 (TAZ) is a transcriptional coactivator and an oncogene in breast and lung cancer. The upstream kinases of the Hippo pathway, mammalian STE20-like kinase 1 and 2 (MST1/2), and large tumor suppressor 1 and 2 (LATS1/2), suppress PD-L1 expression while TAZ and YAP enhance PD-L1 levels in breast and lung cancer cell lines.
Summary
SymbolTAZ
Nametafazzin
Aliases BTHS; G4.5; Barth syndrome; CMD3A; EFE2; EFE; endocardial fibroelastosis 2; cardiomyopathy, dilated 3A (X-li ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TAZ in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.53 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolTAZ
Nametafazzin
Aliases BTHS; G4.5; Barth syndrome; CMD3A; EFE2; EFE; endocardial fibroelastosis 2; cardiomyopathy, dilated 3A (X-li ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TAZ in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.10.732
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2810.873
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0260.985
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4210.202
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.5010.766
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3210.88
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0440.876
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.10.932
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0080.995
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9140.55
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3870.529
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.050.509
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TAZ in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTAZ
Nametafazzin
Aliases BTHS; G4.5; Barth syndrome; CMD3A; EFE2; EFE; endocardial fibroelastosis 2; cardiomyopathy, dilated 3A (X-li ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TAZ. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTAZ
Nametafazzin
Aliases BTHS; G4.5; Barth syndrome; CMD3A; EFE2; EFE; endocardial fibroelastosis 2; cardiomyopathy, dilated 3A (X-li ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TAZ. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TAZ.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTAZ
Nametafazzin
Aliases BTHS; G4.5; Barth syndrome; CMD3A; EFE2; EFE; endocardial fibroelastosis 2; cardiomyopathy, dilated 3A (X-li ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TAZ. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTAZ
Nametafazzin
Aliases BTHS; G4.5; Barth syndrome; CMD3A; EFE2; EFE; endocardial fibroelastosis 2; cardiomyopathy, dilated 3A (X-li ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TAZ expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTAZ
Nametafazzin
Aliases BTHS; G4.5; Barth syndrome; CMD3A; EFE2; EFE; endocardial fibroelastosis 2; cardiomyopathy, dilated 3A (X-li ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TAZ and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTAZ
Nametafazzin
Aliases BTHS; G4.5; Barth syndrome; CMD3A; EFE2; EFE; endocardial fibroelastosis 2; cardiomyopathy, dilated 3A (X-li ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TAZ collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.